Variation in dopamine D2 and serotonin 5-HT2A receptor genes is associated with working memory processing and response to treatment with antipsychotics

Neuropsychopharmacology

Volumn 40, Issue 7, 2015, Pages 1600-1608

  Blasi, Giuseppe ^a,b   Selvaggi, Pierluigi ^a   Fazio, Leonardo ^b   Antonucci, Linda Antonella ^a   Taurisano, Paolo ^a,b   Masellis, Rita ^a   Romano, Raffaella ^a   Mancini, Marina ^a   Zhang, Fengyu ^c   Caforio, Grazia ^a   Popolizio, Teresa ^b   Apud, Jose ^d   Weinberger, Daniel R ^c   Bertolino, Alessandro ^a,e  

^a UNIVERSITY OF BARI   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OXYGEN; SEROTONIN 2A RECEPTOR;

ADULT; ANALYSIS OF VARIANCE; BLOOD; BRAIN; COHORT ANALYSIS; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; HUMAN; IMAGE PROCESSING; MALE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOGENETICS; PHYSIOLOGY; SHORT TERM MEMORY; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULARIZATION; YOUNG ADULT;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BRAIN; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; OXYGEN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; YOUNG ADULT;

EID: 84939996430     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.5     Document Type: Article

References (59)

1. Abi-Dargham A (2007). Alterations of serotonin transmission in schizophrenia. Int Rev Neurobiol 78: 133-164.
2. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS et al (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97: 8104-8109.
3. Albizu L, Holloway T, Gonzalez-Maeso J, Sealfon SC (2011). Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology 61: 770-777.
4. Apud JA, Zhang F, Decot H, Bigos KL, Weinberger DR (2012). Genetic variation in KCNH2 associated with expression in the brain of a unique hERG isoform modulates treatment response in patients with schizophrenia. Am J Psychiatry 169: 725-734.
5. Arranz MJ, Collier DA, Munro J, Sham P, Kirov G, Sodhi M et al (1996). Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 217: 177-178.
6. Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA et al (1998). Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 32: 93-99.
7. Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD et al (2012). Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry 17: 887-905.
8. Beaulieu JM (2012). A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci 37: 7-16.
9. Bertolino A, Blasi G (2009a). The genetics of schizophrenia. Neuroscience 164: 288-299.
10. Bertolino A, Fazio L, Caforio G, Blasi G, Rampino A, Romano R et al (2009b). Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain 132: 417-425.
11. Blasi G, Bertolino A (2006). Imaging genomics and response to treatment with antipsychotics in schizophrenia. NeuroRx 3: 117-130.
12. Blasi G, De Virgilio C, Papazacharias A, Taurisano P, Gelao B, Fazio L et al (2013a). Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment. JAMA Psychiatry 70: 921-930.
13. Blasi G, Goldberg TE, Elvevag B, Rasetti R, Bertolino A, Cohen J et al (2007). Differentiating allocation of resources and conflict detection within attentional control processing. Eur J Neurosci 25: 594-602.
14. Blasi G, Mattay VS, Bertolino A, Elvevag B, Callicott JH, Das S et al (2005). Effect of catechol-O-methyltransferase val158met genotype on attentional control. J Neurosci 25: 5038-5045.
15. Blasi G, Napolitano F, Ursini G, Di Giorgio A, Caforio G, Taurisano P et al (2013b). Association of GSK-3beta genetic variation with GSK-3beta expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia. Am J Psychiatry 170: 868-876.
16. Blasi G, Napolitano F, Ursini G, Taurisano P, Romano R, Caforio G et al (2011). DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci USA 108: 1158-1163.
17. Blasi G, Taurisano P, Papazacharias A, Caforio G, Romano R, Lobianco L et al (2010). Nonlinear response of the anterior cingulate and prefrontal cortex in schizophrenia as a function of variable attentional control. Cereb Cortex 20: 837-845.
18. Bortolozzi A, Diaz-Mataix L, Scorza MC, Celada P, Artigas F (2005). The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 95: 1597-1607.
19. Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R et al (2000). Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 10: 1078-1092.
20. Callicott JH, Egan MF, Mattay VS, Bertolino A, Bone AD, Verchinksi B et al (2003). Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 160: 709-719.
21. Chen SF, Shen YC, Chen CH (2009). HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology (Berl) 205: 285-292.
22. Collins AL, Kim Y, Sklar P, O'Donovan MC, Sullivan PF (2012). Hypothesis-driven candidate genes for schizophrenia compared to genome-wide association results. Psychol Med 42: 607-616.
23. de Bartolomeis A, Buonaguro EF, Iasevoli F (2013). Serotoninglutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology (Berl) 225: 1-19.
24. de Quervain DJ, Henke K, Aerni A, Coluccia D, Wollmer MA, Hock C et al (2003). A functional genetic variation of the 5-HT2a receptor affects human memory. Nat Neurosci 6: 1141-1142.
25. Di Giovanni G, Esposito E, Di Matteo V (2010). Role of serotonin in central dopamine dysfunction. CNS Neurosci Ther 16: 179-194.
26. Di Pietro NC, Seamans JK (2007). Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry 40 Suppl 1: S27-S33.
27. Durstewitz D, Seamans JK (2008). The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia. Biol Psychiatry 64: 739-749.
28. Egan MF, Goldberg TE, Gscheidle T, Weirich M, Rawlings R, Hyde TM et al (2001). Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biol Psychiatry 50: 98-107.
29. Filippini N, Scassellati C, Boccardi M, Pievani M, Testa C, Bocchio-Chiavetto L et al (2006). Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. Eur J Hum Genet 14: 443-449.
30. Fink KB, Gothert M (2007). 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 59: 360-417.
31. First MB, Gibbon M, Spitzer RL, Williams JBW (1996). Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders-Research Version. Biometrics Research: New York, NY, USA.
32. Fuxe K, Borroto-Escuela DO, Tarakanov AO, Romero-Fernandez W, Ferraro L, Tanganelli S et al (2014). Dopamine D2 heteroreceptor complexes and their receptor-receptor interactions in ventral striatum: novel targets for antipsychotic drugs. Prog Brain Res 211: 113-139.
33. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS et al (2003). Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158-Met genotype and schizophrenia. Arch Gen Psychiatry 60: 889-896.
34. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF et al (2008). Identification of a serotonin/ glutamate receptor complex implicated in psychosis. Nature 452: 93-97.
35. Harvey JA (2003). Role of the serotonin 5-HT(2A) receptor in learning. Learn Mem 10: 355-362.
36. Hazelwood LA, Sanders-Bush E (2004). His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation. Mol Pharmacol 66: 1293-1300.
37. Huffaker SJ, Chen J, Nicodemus KK, Sambataro F, Yang F, Mattay V et al (2009). A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med 15: 509-518.
38. Jakab RL, Goldman-Rakic PS (1998). 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA 95: 735-740.
39. Jakab RL, Goldman-Rakic PS (2000). Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. J Comp Neurol 417: 337-348.
40. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE et al (1998). Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44: 1099-1117.
41. Manoach DS (2003). Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res 60: 285-298.
42. Masellis M, Basile V, MeltzerHY, Lieberman JA, Sevy S, Macciardi FM et al (1998). Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19: 123-132.
43. McGuffin P, Riley B, Plomin R (2001). Genomics and behavior. Toward behavioral genomics. Science 291: 1232-1249.
44. Olajossy-Hilkesberger L, Godlewska B, Schosser-Haupt A, Olajossy M, Wojcierowski J, Landowski J et al (2011). Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia. Neuropsychobiology 64: 202-210.
45. Oldfield RC (1971). The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9: 97-113.
46. Ozaki N, Manji H, Lubierman V, Lu SJ, Lappalainen J, Rosenthal NE et al (1997). A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem 68: 2186-2193.
47. Ozaki N, Rosenthal NE, Pesonen U, Lappalainen J, Feldman-Naim S, Schwartz PJ et al (1996). Two naturally occurring amino acid substitutions of the 5-HT2A receptor: similar prevalence in patients with seasonal affective disorder and controls. Biol Psychiatry 40: 1267-1272.
48. Pehek EA, Nocjar C, Roth BL, Byrd TA, Mabrouk OS (2006). Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress-and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 31: 265-277.
49. Rasetti R, Mattay VS, Stankevich B, Skjei K, Blasi G, Sambataro F et al (2010). Modulatory effects of modafinil on neural circuits regulating emotion and cognition. Neuropsychopharmacology 35: 2101-2109.
50. Ripke S, Neale BM, Corvin A, Walters JTR, Farh K, Holmans PA et al (2014). Biological insights from 108 schizophreniaassociated genetic loci. Nature 511: 421-427.
51. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S et al (2013). Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 45: 1150-1159.
52. Sanders AR, Duan J, Levinson DF, Shi J, He D, Hou C et al (2008). No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry 165: 497-506.
53. Schott BH, Seidenbecher CI, Richter S, Wustenberg T, Debska-Vielhaber G, Schubert H et al (2011). Genetic variation of the serotonin 2a receptor affects hippocampal novelty processing in humans. PLoS One 6: e15984.
54. Seamans JK, Yang CR (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74: 1-58.
55. Tan HY, Nicodemus KK, Chen Q, Li Z, Brooke JK, Honea R et al (2008). Genetic variation in AKT1 is linked to dopamineassociated prefrontal cortical structure and function in humans. J Clin Invest 118: 2200-2208.
56. Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M et al (2000). Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408: 199-203.
57. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR (2000). Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 57: 907-913.
58. Williams GV, Rao SG, Goldman-Rakic PS (2002). The physiological role of 5-HT2A receptors in working memory. J Neurosci 22: 2843-2854.
59. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R et al (2007). Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci USA 104: 20552-20557.